

European Journal of Pharmacology 430 (2001) 373-374



www.elsevier.com/locate/ejphar

Rapid communication

Treatment with dehydroepiandrosterone sulfate increases NMDA receptors in hippocampus and cortex

Shao Wen, Kai Dong, Jean Philippe Onolfo, Monique Vincens*

Laboratoire de Pharmacologie Endocrinienne, Groupe Neurostéroides et Cerveau, U.F.R Lariboisière St-Louis (Université Paris VII), 10 Avenue de Verdun 75010 Paris, France

Received 5 September 2001; accepted 7 September 2001

Abstract

Our aim was to investigate if the memory-enhancing effects reported for dehydroepiandrosterone sulfate in rodents could be mediated through modulation of NMDA receptors. Using autoradiography we studied the effect of dehydroepiandrosterone sulfate, administered for 5 days (30 mg/kg, i.p. twice a day), on NMDA binding sites labelled with [³H]dizocilpine ([³H]MK801) in rat brain. Dehydroepiandrosterone sulfate treatment significantly increased the [³H]MK801 binding sites in hippocampal areas (field CA1, CA3, dentate gyrus lateral blade and medial blade) and in cortex layer IV as compared to the control group. These results demonstrate for the first time the ability of dehydroepiandrosterone sulfate to increase the number of NMDA binding sites in rat brain, an action that could be of interest for therapeutic application. © 2001 Elsevier Science B.V. All rights reserved.

Keywords: Dehydroepiandrosterone sulfate; NMDA receptor; Brain; (Rat)

Neurosteroids are present in the central nervous system (CNS) and can be allosteric modulators of neurotransmitter receptors (Vincens et al., 1992). In fact, several metabolites of progesterone such as allopregnanolone and pregnanolone bind to the GABA a receptor complex and are positive allosteric modulators of this GABAA receptor complex (Vincens et al., 1992). Other studies have suggested that pregnenolone sulfate could modulate the NMDA receptor, a subtype of glutamate receptor (Wu et al., 1991). These NMDA receptors are known to be involved in long-term potentiation and in learning and memory (Tsien, 2000). Moreover, dehydroepiandrosterone sulfate, another neurosteroid, has been reported to have significant memory-enhancing effects in vivo in mice (Wolkowitz and Reus, 1996). This effect could result from modulation of NMDA receptors. In order to investigate this hypothesis, we studied in rat brain the effects of dehydroepiandrosterone sulfate treatment on NMDA receptors labelled with the specific ligand [³H]dizocilpine ([³H]MK801) (NEN Boston, MA), which reveals all NMDA receptor subtypes.

Fourteen male Wistar rats (230-250 g) (seven animals per group) received an intraperitoneal (i.p.) injection of

E-mail address: vincens_m@yahoo.com (M. Vincens).

either the vehicle or the substance to be tested, twice a day at 8 and 19 h for 4 days. The last injection was at 8 h on the fifth day. All the animals were killed 2 h after the last injection. The control group received only the vehicle, dimethyl sulfoxide (DMSO, Aldrich; 0.2 ml/250 g body weight (b.w.)). The treated animals received dehydroepiandrosterone sulfate (Sigma; 30 mg/kg b.w.) dissolved in DMSO (0.2 ml/250 g b.w.).

Brain tissues were processed as already described by Vincens et al. (1995). The autoradiographic technique described by Porter and Greenamyre (1995) was used: mounted brain sections were incubated with 7 nM [³H] MK801 (total binding). Alternate sections were incubated with 10⁻⁵ M dizocilpine to assess non-specific binding.

Binding was measured as relative optical density (OD) units. Under these experimental conditions, non-specific labelling density averaged less than 5% of the total [³H]MK801 and was subtracted from the OD readings.

The autoradiographic distribution of [3 H]MK801 specific binding in midbrain of control rats (Fig. 1A) showed that the highest densities of [3 H]MK801 binding sites, expressed as OD (mean \pm S.E.M) were found in cortex (layer II–III, OD: 40.54 ± 1.3) and hippocampus (field CA1, CA3, dentate gyrus, lateral blade and medial blade; ODs are: 44.76 ± 1.5 ; 28 ± 1.7 ; 37.4 ± 1.4 ; 36.2 ± 1.08 , respectively). Intermediate binding sites occurred in cortex (layer IV, OD: 21.3 ± 1.7 ; layer V–VI, OD; 19.1 ± 2.3)

^{*} Corresponding author. Tel.: +33-1-44-89-77-66; fax: +33-1-44-89-78-07




Fig 1. Digitalized image (Biocom, les Ulis, France, RAG-200) of an autoradiographic film showing the density of total [³H]MK801 binding sites in rat midbrain (coronal section at level p29 of the Swanson atlas) control rats (A) and dehydroepiandrosterone sulfate-treated rats (B) (CO: cerebral cortex; HI: hippocampus, 1: field CA1, 2: CA3, 3: dentate gyrus lateral blade, 4: dentate gyrus medial blade; TH: thalamus; LD: lateral dorsal thalamus; VPM: ventral posteromedial nucleus thalamus).

and in thalamus (lateral dorsal thalamus and ventral posteromedial nucleus; ODs: 18.2 ± 2.1 and 17.4 ± 2.3 , respectively).

After dehydroepiandrosterone sulfate treatment, the apparent number of [3 H]MK801 binding sites was significantly increased in hippocampal areas (field CA1, CA3, dentate gyrus lateral blade and medial blade) and in cortex layer IV by 22%, 18%, 13%, 19% and 14%, respectively (OD: $54.01 \pm 1.58^*$; $33.37 \pm 2.1^*$; $42.15 \pm 1.2^*$; $43.13 \pm 1.7^*$; $24.88 \pm 1.8^*$) as compared to the control group ($^*P < 0.01$, $^*P < 0.001$). No significant changes were observed in cortex layers II–III and V–VI and in thalamus (lateral dorsal and ventral posteromedial nucleus) (Fig. 1B).

It is worth noting that this increase was obtained after 5 days of treatment only. A single injection did not induce any modification at 2 h following treatment (data not shown), which does not suggest a change in receptor affinity.

The present data demonstrate for the first time the ability of dehydroepiandrosterone sulfate treatment to in-

crease NMDA binding sites specifically in hippocampus and cortex, structures implicated in memory processes. Since activation of NMDA receptors has been implicated in learning and memory (Tsien, 2000), the improvement of memory by dehydroepiandrosterone sulfate treatment could be the result of an increase of NMDA receptors. These findings are of special interest since NMDA receptors decrease with age in rodents and humans. A decrease was also found in the brain of patients with senile dementia of Alzheimer's type (Ulas et al., 1992). Therefore, a decline in this receptor might underlie age-related deficiencies in learning and memory.

Moreover, a physiological decrease in dehydroepiandrosterone and dehydroepiandrosterone sulfate plasma levels in both men and women has been reported with ageing (Ravaglia et al., 1996).

These findings, together with the fact that during ageing, a physiological decrease of NMDA receptors and dehydroepiandrosterone sulfate plasma levels is observed in humans, make it of great interest to prevent the decrease in NMDA receptors by treatment with dehydroepiandrosterone sulfate, at the time of the decline of dehydroepiandrosterone sulfate plasma levels in both men and women.

References

Porter, R.H., Greenamyre, T., 1995. Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J. Neurochem. 64, 614–623.

Ravaglia, G., Forti, P., Maioli, F., Boschi, F., Bernardi, M., Pratelli, L., Pizzoferrato, A., Gasbarrini, G., 1996. The relationship of Dehydroepiandrosterone sulfate (DHEAS) to endocrine-metabolic parameters and functional status in the oldest-old. Results from an Italian study on healthy free-living over-ninety-year-olds. J. Clin. Endocrinol. Metab. 81, 1173–1178.

Tsien, J.Z., 2000. Linking Hebb's coincidence-detection to memory formation. Curr. Opin. Neurobiol. 10, 266–273.

Ulas, J., Brunner, L.C., Geddes, J.W., Choe, W., Cotman, C.W., 1992.
N-methyl-D-aspartate receptor complex in the hippocampus of elderly, normal individuals and those with Alzheimer's disease. Neuroscience 49, 45–61.

Vincens, M., Shu, C., Fortin, M., Philibert, D., Gaillard-Moguilewsky, M., 1992. Comparison between the interaction of steroids with [³⁵S]-TBPS binding to cerebral cortical and to pituitary membranes: Correlation with inhibition of prolactin release. Naunyn-Schmiedeberg's Arch. Pharmacol. 46, 523–526.

Vincens, M., Dartois, E., Moyse, E., Haour, F., Fillion, G., 1995. An autoradiographic study comparing the interaction of 3a-OH-5α-pregnan-20-one, pregnenolone sulfate and pentobarbital with [35S]TBPS binding sites and their modulation by GABA in different structures of rat brain. Naunnyn-Schmiedeberg's Arch. Pharmacol. 351, 356–362.

Wolkowitz, O.M., Reus, V.I., 1996. Dehydroepiandrosterone treatment of depression and memory disorders. In: Genazzani, A.R., Petraglia, F., Purdy, R.H. (Eds.), The Brain: Source and Target for Sex Steroid Hormones. The Parthenon Publishing Group, New York, pp. 243–256.

Wu, F.S., Gibbs, T.T., Farb, D.H., 1991. Pregnenolone sulfate: a positive allosteric modulator at the *N*-methyl-D-aspartate receptor. Mol. Pharmacol. 40, 333–336.